iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity PipelineMarketBeat • Thursday
iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate UpdateGlobeNewsWire • Tuesday
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 TherapyGlobeNewsWire • 10/13/26
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/28/26
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical OfficerGlobeNewsWire • 08/04/26
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP StudyGlobeNewsWire • 07/01/26
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with ObesityGlobeNewsWire • 06/02/26
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/12/26
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in AustraliaGlobeNewsWire • 04/08/26
iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure TranscriptSeeking Alpha • 03/18/26
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewsWire • 03/16/26
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight LossGlobeNewsWire • 03/09/26
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/10/26
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 02/02/26
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/12/25
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight MaintenanceGlobeNewsWire • 10/30/25
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewsWire • 10/23/25
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025GlobeNewsWire • 10/21/25
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 09/05/25